Reply to "Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?"

Cancer. 2023 Apr 1;129(7):1131-1132. doi: 10.1002/cncr.34659. Epub 2023 Jan 24.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Bile Duct Neoplasms*
  • CTLA-4 Antigen
  • Humans
  • Melanoma*
  • Programmed Cell Death 1 Receptor / immunology

Substances

  • Antibodies, Monoclonal
  • CTLA-4 Antigen
  • Programmed Cell Death 1 Receptor